Paul Tudor Jones's TEVA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 500,000 shares of Teva Pharmaceutical Industries Limited (TEVA) worth $15.6 M, representing 0.03% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in TEVA, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 700,087 shares. Largest reduction occurred in Q2 2023, reducing 472,253 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -150,000 | Reduce 23.08% | 500,000 | $31.21 |
| Q2 2025 | -47,457 | Reduce 6.80% | 650,000 | $16.76 |
| Q1 2025 | +247,456 | Add 54.99% | 697,457 | $15.37 |
| Q4 2024 | -365,000 | Reduce 44.79% | 450,001 | $22.04 |
| Q3 2024 | -40,000 | Reduce 4.68% | 815,001 | $18.02 |
| Q2 2024 | -90,048 | Reduce 9.53% | 855,001 | $16.25 |
| Q1 2024 | -11,288 | Reduce 1.18% | 945,049 | $14.11 |
| Q4 2023 | +61,836 | Add 6.91% | 956,337 | $10.44 |
| Q3 2023 | +208,776 | Add 30.45% | 894,501 | $10.20 |
| Q2 2023 | -472,253 | Reduce 40.78% | 685,725 | $7.53 |
| Q1 2023 | +11,859 | Add 1.03% | 1.16 M | $0.01 |
| Q4 2022 | +21,032 | Add 1.87% | 1.15 M | $0.01 |
| Q3 2022 | +10,000 | Add 0.90% | 1.13 M | $8.07 |
| Q2 2022 | +415,000 | Add 59.28% | 1.12 M | $7.52 |
| Q1 2022 | +700,087 | New Buy | 700,087 | $9.39 |
| Q4 2020 | -10,174 | Sold Out | 0 | $0.00 |
| Q3 2020 | +10,174 | New Buy | 10,174 | $9.04 |
| Q2 2020 | -10,100 | Sold Out | 0 | $0.00 |
| Q1 2020 | -496 | Reduce 4.68% | 10,100 | $9.01 |
| Q4 2019 | +10,596 | New Buy | 10,596 | $9.82 |
| Q4 2016 | -5,930 | Sold Out | 0 | $0.00 |
| Q3 2016 | +5,930 | New Buy | 5,930 | $46.04 |
| Q2 2016 | -10,782 | Sold Out | 0 | $0.00 |
| Q1 2016 | -389,218 | Reduce 97.30% | 10,782 | $53.52 |
| Q4 2015 | +389,700 | Add 3783.50% | 400,000 | $65.64 |
| Q3 2015 | -389,700 | Reduce 97.42% | 10,300 | $56.50 |
| Q2 2015 | -150,000 | Reduce 27.27% | 400,000 | $59.10 |
| Q1 2015 | +550,000 | New Buy | 550,000 | $62.30 |
| Q2 2014 | -300,000 | Sold Out | 0 | $0.00 |
| Q1 2014 | +300,000 | New Buy | 300,000 | $52.84 |
Paul Tudor Jones's Teva Pharmaceutical Industries Limited Investment FAQs
Paul Tudor Jones first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q1 2014, acquiring 300,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Teva Pharmaceutical Industries Limited (TEVA) for 31 quarters since Q1 2014.
Paul Tudor Jones's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q1 2022, adding 700,087 shares worth $6.57 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 500,000 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $15.6 M.
As of the Q4 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 0.03% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 1,157,978 shares, as reported at the end of Q1 2023.